Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
Breast cancer
Interim analysis
Phase II study
Ultra-hypofractionated radiation therapy
Whole-breast irradiation
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
received:
18
01
2024
accepted:
24
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study. We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis-T3 N0-N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months. Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected. Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.
Sections du résumé
BACKGROUND
BACKGROUND
The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study.
METHODS
METHODS
We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis-T3 N0-N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months.
RESULTS
RESULTS
Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected.
CONCLUSIONS
CONCLUSIONS
Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.
Identifiants
pubmed: 38607499
doi: 10.1007/s12282-024-01577-3
pii: 10.1007/s12282-024-01577-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2 .
doi: 10.1016/S0140-6736(11)61629-2
pubmed: 22019144
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:452–78. https://doi.org/10.6004/jnccn.2020.0016 .
doi: 10.6004/jnccn.2020.0016
pubmed: 32259783
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145–52. https://doi.org/10.1016/j.prro.2018.01.012 .
doi: 10.1016/j.prro.2018.01.012
pubmed: 29545124
Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, et al. A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol. 2019;49:57–62. https://doi.org/10.1093/jjco/hyy160 .
doi: 10.1093/jjco/hyy160
pubmed: 30428042
Nozaki M, Kagami Y, Machida R, Nakamura K, Ito Y, Nishimura Y, et al. Final analysis of a multicenter single-arm confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol. 2021;51:865–72. https://doi.org/10.1093/jjco/hyab024 .
doi: 10.1093/jjco/hyab024
pubmed: 33728450
Aibe N, Karasawa K, Aoki M, Akahane K, Ogawa Y, Ogo E, et al. Results of a nationwide survey on Japanese clinical practice in breast-conserving radiotherapy for breast cancer. J Radiat Res. 2019;60:142–9. https://doi.org/10.1093/jrr/rry095 .
doi: 10.1093/jrr/rry095
pubmed: 30476198
Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, et al. The Japanese breast cancer society clinical practice guideline for radiation treatment of breast cancer 2018 edition. Breast Cancer. 2020;27:9–16. https://doi.org/10.1007/s12282-019-01019-5 .
doi: 10.1007/s12282-019-01019-5
pubmed: 31659711
Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward trial. Radiother Oncol. 2016;120:114–8. https://doi.org/10.1016/j.radonc.2016.02.027 .
doi: 10.1016/j.radonc.2016.02.027
pubmed: 27046390
pmcid: 4998960
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6 .
doi: 10.1016/S0140-6736(20)30932-6
pubmed: 32580883
pmcid: 7262592
Eckstein J, Taylor P, Zheng R, Lee L, Chen W, Potters L, et al. Implementation of external beam five-fraction adjuvant breast irradiation in a US center. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14061556 .
doi: 10.3390/cancers14061556
pubmed: 36230733
pmcid: 9311974
Sigaudi V, Zannetti M, Ferrara E, Manfredda I, Mones E, Loi G, et al. Ultra-hypofractionation for whole-breast irradiation in early breast cancer: interim analysis of a prospective study. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10102568 .
doi: 10.3390/biomedicines10102568
pubmed: 36289830
pmcid: 9599048
Abdelkarem OAI, Choudhury A, Burnet NG, Summersgill HR, West CML. Effect of race and ethnicity on risk of radiotherapy toxicity and implications for radiogenomics. Clin Oncol (R Coll Radiol). 2022;34:653–69. https://doi.org/10.1016/j.clon.2022.03.013 .
doi: 10.1016/j.clon.2022.03.013
pubmed: 35431121
Diao K, Lei X, He W, Jagsi R, Giordano SH, Smith GL, et al. Racial and ethnic differences in long-term adverse radiation therapy effects among breast cancer survivors. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.09.023 .
doi: 10.1016/j.ijrobp.2023.09.023
pubmed: 37751792
Mitsuyoshi T, Ono Y, Ashida R, Yamashita M, Tanabe H, Takebe S, et al. Multi-institutional phase II study of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for breast cancer in Japan: Kyoto radiation oncology study group (UPBEAT study). Jpn J Clin Oncol. 2023;53:174–8. https://doi.org/10.1093/jjco/hyac174 .
doi: 10.1093/jjco/hyac174
pubmed: 36420578
Wolf J, Stoller S, Lübke J, Rothe T, Serpa M, Scholber J, et al. Deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a single-institution retrospective dosimetric analysis of organs at risk doses. Strahlenther Onkol. 2023;199:379–88. https://doi.org/10.1007/s00066-022-01998-z .
doi: 10.1007/s00066-022-01998-z
pubmed: 36074138
Degrande FAM, Marta GN, Alves TMMT, Ferreira GBS, Dumaszak FV, Carvalho HA, et al. Deep inspiration breath hold: dosimetric benefits to decrease cardiac dose during postoperative radiation therapy for breast cancer patients. Rep Pract Oncol Radiother. 2023;28:172–80. https://doi.org/10.5603/RPOR.a2023.0027 .
doi: 10.5603/RPOR.a2023.0027
pubmed: 37456706
pmcid: 10348328
Van Hulle H, Vakaet V, Monten C, Deseyne P, Schoepen M, Colman C, et al. Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost. Breast. 2021;55:105–11. https://doi.org/10.1016/j.breast.2020.12.009 .
doi: 10.1016/j.breast.2020.12.009
pubmed: 33401157
Montero A, CiÈrvide R, CaÒadillas C, Álvarez B, GarcÌa-Aranda M, Alonso R, et al. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer. Clin Transl Radiat Oncol. 2023;41:100651. https://doi.org/10.1016/j.ctro.2023.100651 .
doi: 10.1016/j.ctro.2023.100651
pubmed: 37388711
pmcid: 10300060
Osako T, Oguchi M, Kumada M, Nemoto K, Iwase T, Yamashita T. Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy. Jpn J Clin Oncol. 2008;38:334–8. https://doi.org/10.1093/jjco/hyn030 .
doi: 10.1093/jjco/hyn030
pubmed: 18417501
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17. https://doi.org/10.1016/j.radonc.2005.01.005 .
doi: 10.1016/j.radonc.2005.01.005
pubmed: 15878095